Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7474
- TODAY'S CHANGE (%)-0.0045 (-0.5985%)
- Bid / Lots0.7474/ 6
- Ask / Lots0.7589/ 6
- Open / Previous Close0.7559 / 0.7519
- Day Range
- 52 Week Range
- Volume150,870
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 16136 | 0.7519 |
| 09:34 ET | 16617 | 0.7519 |
| 09:36 ET | 12327 | 0.7487 |
| 09:39 ET | 1310 | 0.7226 |
| 09:41 ET | 500 | 0.728426 |
| 09:43 ET | 1400 | 0.7283 |
| 09:45 ET | 555 | 0.7429 |
| 09:50 ET | 4200 | 0.745 |
| 09:52 ET | 920 | 0.745 |
| 09:54 ET | 600 | 0.745 |
| 09:56 ET | 100 | 0.745 |
| 09:57 ET | 346 | 0.745 |
| 10:01 ET | 200 | 0.745 |
| 10:03 ET | 800 | 0.7475 |
| 10:06 ET | 337 | 0.7475 |
| 10:08 ET | 100 | 0.7473 |
| 10:10 ET | 1295 | 0.7308 |
| 10:12 ET | 100 | 0.7475 |
| 10:14 ET | 200 | 0.7474 |
| 10:15 ET | 300 | 0.7363 |
| 10:17 ET | 200 | 0.7474 |
| 10:19 ET | 200 | 0.73995 |
| 10:21 ET | 200 | 0.7474 |
| 10:24 ET | 7302 | 0.73 |
| 10:26 ET | 2500 | 0.7301 |
| 10:30 ET | 552 | 0.734875 |
| 10:35 ET | 100 | 0.744 |
| 10:37 ET | 100 | 0.744 |
| 10:42 ET | 100 | 0.745 |
| 10:44 ET | 350 | 0.738999 |
| 10:46 ET | 100 | 0.733 |
| 10:48 ET | 300 | 0.745 |
| 10:50 ET | 200 | 0.745 |
| 10:51 ET | 2650 | 0.745 |
| 10:53 ET | 400 | 0.745 |
| 10:55 ET | 200 | 0.745 |
| 10:57 ET | 1231 | 0.7355 |
| 11:00 ET | 100 | 0.745 |
| 11:02 ET | 200 | 0.7455 |
| 11:04 ET | 100 | 0.7455 |
| 11:06 ET | 200 | 0.7455 |
| 11:08 ET | 600 | 0.74125 |
| 11:09 ET | 200 | 0.7467 |
| 11:11 ET | 650 | 0.7467 |
| 11:13 ET | 2530 | 0.7489 |
| 11:15 ET | 100 | 0.7519 |
| 11:18 ET | 200 | 0.7519 |
| 11:20 ET | 329 | 0.7494 |
| 11:22 ET | 200 | 0.7494 |
| 11:29 ET | 14643 | 0.7523 |
| 11:31 ET | 100 | 0.752 |
| 11:33 ET | 100 | 0.7523 |
| 11:38 ET | 100 | 0.7521 |
| 11:40 ET | 100 | 0.7521 |
| 11:42 ET | 900 | 0.7521 |
| 11:44 ET | 100 | 0.7521 |
| 11:45 ET | 100 | 0.7521 |
| 11:47 ET | 600 | 0.747 |
| 11:49 ET | 719 | 0.735 |
| 11:51 ET | 200 | 0.7425 |
| 11:54 ET | 200 | 0.7425 |
| 11:56 ET | 100 | 0.735 |
| 12:02 ET | 100 | 0.735 |
| 12:05 ET | 100 | 0.735 |
| 12:09 ET | 100 | 0.735 |
| 12:14 ET | 100 | 0.7355 |
| 12:27 ET | 200 | 0.7359 |
| 12:41 ET | 132 | 0.7515 |
| 12:50 ET | 141 | 0.7439 |
| 01:01 ET | 100 | 0.7364 |
| 01:15 ET | 100 | 0.737 |
| 01:19 ET | 266 | 0.7513 |
| 01:21 ET | 300 | 0.7514 |
| 01:26 ET | 1600 | 0.7514 |
| 01:33 ET | 101 | 0.7514 |
| 01:37 ET | 200 | 0.7514 |
| 01:39 ET | 1747 | 0.749497 |
| 01:42 ET | 100 | 0.7514 |
| 01:44 ET | 5171 | 0.7519 |
| 01:46 ET | 200 | 0.7519 |
| 01:48 ET | 972 | 0.7524 |
| 01:51 ET | 200 | 0.76 |
| 01:55 ET | 100 | 0.76 |
| 01:57 ET | 100 | 0.76 |
| 02:00 ET | 100 | 0.76 |
| 02:06 ET | 2244 | 0.7592 |
| 02:08 ET | 1000 | 0.7578 |
| 02:09 ET | 1161 | 0.7609 |
| 02:13 ET | 100 | 0.7644 |
| 02:18 ET | 264 | 0.7643 |
| 02:20 ET | 100 | 0.7637 |
| 02:22 ET | 380 | 0.7637 |
| 02:26 ET | 700 | 0.7636 |
| 02:29 ET | 100 | 0.7489 |
| 02:31 ET | 8440 | 0.7366 |
| 02:33 ET | 300 | 0.7455 |
| 02:36 ET | 100 | 0.7411 |
| 02:42 ET | 3321 | 0.7411 |
| 02:44 ET | 300 | 0.7499 |
| 02:45 ET | 400 | 0.7502 |
| 02:47 ET | 100 | 0.7589 |
| 02:49 ET | 200 | 0.7589 |
| 02:51 ET | 550 | 0.7589 |
| 02:54 ET | 375 | 0.7589 |
| 02:56 ET | 100 | 0.7589 |
| 02:58 ET | 300 | 0.7447 |
| 03:02 ET | 100 | 0.7474 |
| 03:05 ET | 200 | 0.7589 |
| 03:07 ET | 100 | 0.7474 |
Apr 10, 2024
DJ Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham, from 6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:45AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 41.1M | -0.3x | --- |
ImmuCell Corp | 38.1M | -6.8x | --- |
Prenetics Global Ltd | 61.6M | -1.1x | --- |
Aadi Bioscience Inc | 47.1M | -0.8x | --- |
Turnstone Biologics Corp | 60.1M | -1.0x | --- |
Viaderma Inc | 11.9M | 0.0x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Senior Vice President - Research and Development, Chief Scientific Officer
- Frederique Menzaghi
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.1M |
|---|---|
Revenue (TTM) | $21.0M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $-2.19 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -579.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
